Last $0.18 USD
Change Today -0.0049 / -2.65%
Volume 6.0K
CAPS On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 05/24/13 All times are local (Market data is delayed by at least 15 minutes).

capstone therapeutics corp (CAPS) Snapshot

Open
$0.21
Previous Close
$0.19
Day High
$0.21
Day Low
$0.18
52 Week High
02/8/13 - $0.26
52 Week Low
09/21/12 - $0.12
Market Cap
7.4M
Average Volume 10 Days
11.1K
EPS TTM
$-0.13
Shares Outstanding
40.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CAPSTONE THERAPEUTICS CORP (CAPS)

Related News

No related news articles were found.

capstone therapeutics corp (CAPS) Related Businessweek News

No Related Businessweek News Found

capstone therapeutics corp (CAPS) Details

Capstone Therapeutics Corp., a biotechnology company, focuses on developing therapeutic peptides for helping patients with under-served medical conditions. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

2 Employees
Last Reported Date: 03/14/13
Founded in 1987

capstone therapeutics corp (CAPS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $145.0K
Consultant
Total Annual Compensation: $145.0K
Compensation as of Fiscal Year 2012.

capstone therapeutics corp (CAPS) Key Developments

Capstone Therapeutics Corp. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013

Capstone Therapeutics Corp. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported loss from continuing operations before taxes of $1,188,000 compared to $976,000 for the same period a year ago. Loss from continuing operations was $1,188,000 compared to $976,000 for the same period a year ago. Net loss was $1,188,000 compared to $976,000 for the same period a year ago. Net loss attributable to the company stockholders was $995,000 compared to $976,000 for the same period a year ago. Net loss per share, basic and diluted, attributable to the company stockholders was $0.02 compared to $0.02 for the same period a year ago. The net loss benefited from effect of the reduction in internal operations and receipt of $152,000 from the conversion of an insurance company, in which the company was a policyholder, from mutual to private ownership, but these beneficial effects were offset by inclusion of the operating expenses of joint venture, LipimetiX Development, LLC.

Capstone Therapeutics Corp., Q1 2013 Earnings Call, May 15, 2013

Capstone Therapeutics Corp., Q1 2013 Earnings Call, May 15, 2013

Capstone Therapeutics Corp. Reports Consolidated Earnings Results for the Year Ended December 31, 2012

Capstone Therapeutics Corp. reported consolidated earnings results for the year ended December 31, 2012. For the period, the company reported loss from continuing operations was $4.053 million compared to $9.711 million for the same period last year. Net loss was $4.053 million compared to $9.711 million for the same period last year. Net loss attributable to the company stockholders were $3.58 million or $0.09 per basic and diluted share compared to $9.711 million or $0.24 per basic and diluted share for the same period last year. Cash flows used in operating activities was $3.367 million compared to $10.59 million for the same period last year. Expenditures for furniture and equipment, net were nil compared to $19,000 for the same period last year. The decrease in the net loss for the year ended December 31, 2012 compared to 2011 resulted primarily from the reduction in staff in the fourth quarter of 2011 and other actions taken by the Company to wind down internal operations and move to a virtual operating model. Loss from continuing operations before taxes was $4.053 million compared to $9.869 million for the same period last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CAPS:US $0.18 USD -0.0049

CAPS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CAPS.
View Industry Companies
 

Industry Analysis

CAPS

Industry Average

Valuation CAPS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAPSTONE THERAPEUTICS CORP, please visit www.capstonethx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.